Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor*

  title={Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor*},
  author={Pari Malherbe and Nicole A. Kratochwil and Frédéric Knoflach and Marie‐Th{\'e}r{\`e}se Zenner and James N. C. Kew and Claudia Kratzeisen and H. P. Maerki and Geo Adam and Vincent Mutel},
  journal={The Journal of Biological Chemistry},
  pages={8340 - 8347}
A model of the rmGlu1 seven-transmembrane domain complexed with a negative allosteric modulator, 1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)- 1,6-dihydro-pyrimidine-5-carbonitrile (EM-TBPC) was constructed. Although the mGlu receptors belong to the family 3 G-protein-coupled receptors with a low primary sequence similarity to rhodopsin-like receptors, the high resolution crystal structure of rhodopsin was successfully applied as a template in this model and used to select… 

Figures and Tables from this paper

Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine.
A striking similarity between the critical residues involved in MPEP-binding site with those of previously identified as 1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydropyrimidine-5-carbonitrile-binding pocket of mGlu1 is pointed to a common mechanism of inhibition shared by both antagonists.
Modeling and Mutagenesis of the Binding Site of Calhex 231, a Novel Negative Allosteric Modulator of the Extracellular Ca2+-sensing Receptor*
The crystal structure of bovine rhodopsin exhibits sufficient mimicry to the ground state of a very divergent class 3 receptor to predict the interaction of antagonists with the heptahelical bundle of diverse G-protein-coupled receptors.
Point Mutations in the Transmembrane Region of GABAB2 Facilitate Activation by the Positive Modulator N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) in the Absence of the GABAB1 Subunit
The data show that mutations of specific amino acids in GB2 can induce agonism in addition to positive modulation and facilitate GB2 activation in the absence of GB1, and identify a key region for the effect of GS39783 in the GB2 transmembrane region.
ONIOM and FMO-EDA study of metabotropic glutamate receptor 1: Quantum insights into the allosteric binding site
The crystal structure of metabotropic glutamate receptor 1 (mGluR1) complexed with 4-fluoro-N-(4-(6-(isopropylamino)pyrimidin-4-yl)thiazol-2-yl)-N-methylbenzamide (FITM, a negative allosteric
A Novel Class of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Interact with a Site Distinct from That of Negative Allosteric Modulators
Analysis of CDPPB analogs and site-directed mutagenesis suggest that valine at position 757 in transmembrane V of mGluR1a is crucial for the activity of multiple classes of allosteric mGLUR1 potentiators.
Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2.
It is proposed that this allosteric binding site defines a pocket that is different from the orthosteric site located in the amino terminal domain at hmGluR2, and is also observed to a greater extent on the concentration-response curves to selective hmR2/3 agonists.
Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP
The site‐directed mutagenesis coupled with three‐dimensional receptor‐based pharmacophore modelling is used to elucidate the interacting mode of fenobam within the seven‐transmembrane domain (7TMD) of mGlu5 receptor and its comparison with that of 2‐methyl‐6‐(phenylethynyl)pyridine (MPEP), the prototype antagonist.
Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists.
The relationship between receptor occupancy and in vivo pharmacological activity of mGluR1 antagonists was clarified and receptor occupancy assays could help provide guidelines for selecting appropriate doses of allosteric mGLUR1 antagonist for examining the function of mR1 in vivo.


The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors*
Results indicate that MPEP and CPCCOEt bind to overlapping binding pockets in the TM region of group I mGluRs but interact with different non-conserved residues.
Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor*
Several residues of the human A3 adenosine receptor within transmembrane domains 3 and 6 and the second extracellular loop, which have been predicted by previous molecular modeling to be involved in the ligand recognition, were mutated, indicating that Trp243 was critical for receptor activation.
Identification of essential residues involved in the glutamate binding pocket of the group II metabotropic glutamate receptor.
Results suggest that Ser-148 and Arg-183 may be important for the 3D structure and/or are involved in closure of the domain, and Asp-146, which is also remote from the binding site, was shown to be involved in the differential binding affinity of [(3)H]LY354740 for mGlu2 versus mGLU3 receptors.
Computational Model of the Complex between GR113808 and the 5-HT4 Receptor Guided by Site-Directed Mutagenesis and the Crystal Structure of Rhodopsin
A computational model of the transmembrane domain of the human 5-HT4 receptor complexed with the GR113808 antagonist was constructed from the crystal structure of rhodopsin and the putative residues of the ligand-binding site, experimentally determined by site-directed mutagenesis to help understand the binding of related ligands to their cognate receptors.
Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501.
It is shown that CGP7930 enhances the inhibitory effect of L-baclofen on the oscillatory activity of cultured cortical neurons and may represent a novel means of therapeutic interference with the GABA-ergic system.
Mapping the Agonist-binding Site of GABAB Type 1 Subunit Sheds Light on the Activation Process of GABABReceptors*
The data demonstrate the pivotal role played by the GABAB1 subunit in the activation of the heteromeric GABAB receptor and are consistent with the idea that a closed state of the binding domain of family 3 receptors is required for their activation.
CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.
It is proposed that the interaction of CPCCOEt with Thr815 and Ala818 of mGluR1 disrupts receptor activation by inhibiting an intramolecular interaction between the agonist-bound extracellular domain and the transmembrane domain.
Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors.
It is proposed that the overall structures of rhodopsin and of amine receptors are very similar, although there are also localized regions where the structure of these receptors may diverge.
BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity.
BAY36-7620 will be useful to further delineate the functional importance of the mGlu1 receptor, including its putative agonist-independent activity, andTransmembrane helices 4 to 7 are shown to play a critical role in the selectivity of BAY36- 7620.